Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
- Drug Discovery
- Stem cells
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 306186
(a) develop, use, demonstrate, sell, offer for sale, market, distribute, and promote Products in the Territory for use in the Field, exclusively,
(b) import Products into the Territory for use in the Field; exclusively;
(c) test and conduct independent Phase 3 clinical studies/trials on or Products in in the Territory, exclusively, and,
(d) manufacture, have manufactured, the Products solely in mainland China solely for use in the Territory and in the Field, non-exclusively.
Compound means Ad5FGF-4, alferminogene tadenovec, an angiogenic gene therapeutic, and natural evolutions thereof.
Product shall mean any biopharmaceutical product containing the Compound, alone or in combination with one or more other active pharmaceutical ingredients, in any dosage form or formulation, including any lyophilized forms thereof.
The initial medical indication will be for the treatment of patients with refractory angina due to ischemic heart disease.
Ischemic heart disease is a condition of recurring chest pain or discomfort that occurs when a part of the heart does not receive enough blood. This condition occurs most often during exertion or excitement, when the heart requires greater blood flow.
IPSCIO Record ID: 90513
'Product' refers to any biopharmaceutical product containing the Compound, alone or in combination with one or more other active pharmaceutical ingredients, in any dosage form or formulation, including any lyophilized forms thereof. The product is an angiogenic gene therapy treatment, known as Generx.
Refractory angina (RA) is conventionally defined as a chronic condition characterised by angina in the setting of coronary artery disease (CAD),
IPSCIO Record ID: 28042
IPSCIO Record ID: 3533
The patents relate to certain gene therapy applications of the membrane-bound form of the Stem Cell Factor gene (mSCF) for treatment of cardiac ischemia.
The Licensor intellectual property and research involves gene therapy technologies.
IPSCIO Record ID: 328338
For Other Indications for Licensed Compounds, Licensor grants a right of first refusal to obtain licenses to use Licensed Compounds for other applications or indications outside the Field.
For Rights to Related Compounds. Licensor grants the right to include within the license rights granted under the License specific Related Compounds.
The Parties are to develop and commercialize LR-3280 and certain related oligonucleotide compounds in Japan and certain other countries in Asia for the prevention or treatment of restenosis in any blood vessel following an angioplasty or similar procedure, and Licensor will supply Licensee quantities of product containing such compounds for clinical use and commercial sale.
The patents subject matter includes but is not limited to
– Method of inhibition smooth muscle cell proliferation by treating with c-myc antisense;
– Method of treating restenosis by administrating c-myr antisense;
– Method of Inhibiting collagen synthesis by treating with c-myr antisense;
– Method of treating vascular grafts to reduce stenosis by applying c-myr antisense to graft; and,
– Pharmaceutical compositions for the above methods.
Licensed Compounds means the oligonucleotide compound identified by Licensor as LR-3280, and any other phosphorothioated oligonucleotidc compounds that now or hereafter are owned or Controlled by Licensor or its Affiliates and that specifically target the mRNA transcribed from the c-myc gene, or contain four deoxyguanosine nucleotides in a row and are developed by Licensor for use in the Field.
Clinical Trial Product means a product, appropriate for use in clinical trials, containing a Licensed Compound or placebo, as applicable, in the formulation as determined by Licensee.
Restenosis is the recurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed.